1.23
price down icon5.38%   -0.07
after-market Handel nachbörslich: 1.27 0.04 +3.25%
loading

An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten

pulisher
Nov 20, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease - Business Wire

Nov 20, 2024
pulisher
Nov 18, 2024

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting - Business Wire

Nov 18, 2024
pulisher
Nov 18, 2024

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 15, 2024

Grace Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire

Nov 13, 2024
pulisher
Nov 12, 2024

22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail

Nov 12, 2024
pulisher
Oct 31, 2024

Cognition Therapeutics Presents Poster of Participant - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - BioSpace

Oct 31, 2024
pulisher
Oct 29, 2024

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease - StockTitan

Oct 28, 2024
pulisher
Oct 25, 2024

Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain - GlobeNewswire

Oct 25, 2024
pulisher
Oct 24, 2024

Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire

Oct 24, 2024
pulisher
Oct 24, 2024

Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ... - Yahoo Finance

Oct 24, 2024
pulisher
Oct 23, 2024

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire

Oct 23, 2024
pulisher
Oct 22, 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Yahoo Finance

Oct 22, 2024
pulisher
Oct 17, 2024

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire

Oct 17, 2024
pulisher
Oct 16, 2024

Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha

Oct 16, 2024
pulisher
Oct 15, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - Yahoo Finance

Oct 15, 2024
pulisher
Oct 11, 2024

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - GlobeNewswire

Oct 11, 2024
pulisher
Oct 09, 2024

Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire

Oct 09, 2024
pulisher
Oct 08, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Business Wire

Oct 08, 2024
pulisher
Oct 07, 2024

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire

Oct 07, 2024
pulisher
Oct 04, 2024

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - StockTitan

Oct 04, 2024
pulisher
Oct 02, 2024

Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire

Oct 02, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire

Oct 01, 2024
pulisher
Sep 25, 2024

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

Araris Doubles Down With Dual-payload ADC - BioProcess Online

Sep 24, 2024
pulisher
Sep 23, 2024

Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa

Sep 23, 2024
pulisher
Sep 23, 2024

Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser

Sep 23, 2024
pulisher
Sep 23, 2024

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations - StockTitan

Sep 23, 2024
pulisher
Sep 22, 2024

Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire

Sep 22, 2024
pulisher
Sep 22, 2024

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance

Sep 22, 2024
pulisher
Sep 22, 2024

Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record

Sep 22, 2024
pulisher
Sep 21, 2024

Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa

Sep 21, 2024
pulisher
Sep 20, 2024

Adicet Bio reports promising ADI-001 therapy data - Investing.com

Sep 20, 2024
pulisher
Sep 19, 2024

Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM

Sep 19, 2024
pulisher
Sep 19, 2024

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting - BioSpace

Sep 19, 2024
pulisher
Sep 19, 2024

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Sep 19, 2024
pulisher
Sep 19, 2024

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire

Sep 19, 2024
pulisher
Sep 18, 2024

Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disease - Ophthalmology Times

Sep 18, 2024
pulisher
Sep 17, 2024

VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire

Sep 17, 2024
pulisher
Sep 17, 2024

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire

Sep 17, 2024
pulisher
Sep 16, 2024

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 - Yahoo Finance

Sep 16, 2024
pulisher
Sep 14, 2024

Acrivon Therapeutics Reports Positive Endometrial Cancer - GlobeNewswire

Sep 14, 2024
pulisher
Sep 12, 2024

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire

Sep 12, 2024
pulisher
Sep 12, 2024

Intellia Therapeutics to Present Data from the Phase 2 - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance

Sep 12, 2024
pulisher
Sep 11, 2024

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - GlobeNewswire

Sep 11, 2024
pulisher
Sep 10, 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Newsfile

Sep 10, 2024
pulisher
Sep 10, 2024

Pliant Therapeutics Presents Data from its Bexotegrast - GlobeNewswire

Sep 10, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - GlobeNewswire

Sep 09, 2024
pulisher
Sep 03, 2024

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Yahoo Finance

Sep 03, 2024
pulisher
Sep 03, 2024

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) - GlobeNewswire

Sep 03, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):